A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma (Q42317241)
Jump to navigation
Jump to search
scientific article published on 28 February 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma |
scientific article published on 28 February 2017 |
Statements
1 reference
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma (English)
1 reference
Al B Benson
1 reference
Zev A Wainberg
1 reference
J Randolph Hecht
1 reference
Dmitry Vyushkov
1 reference
Hua Dong
1 reference
Johanna Bendell
1 reference
Fred Kudrik
1 reference
28 February 2017
1 reference
1 reference
241-e15
1 reference
Identifiers
1 reference
1 reference
1 reference